| Scientific white paper on concentration-QTc modeling |
37 |
| A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim |
12 |
| Fractional calculus in pharmacokinetics |
10 |
| How to mathematically optimize drug regimens using optimal control |
7 |
| Development of a nonlinear hierarchical model to describe the disposition of deuterium in mother-infant pairs to assess exclusive breastfeeding practice |
6 |
| Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization |
6 |
| Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics |
6 |
| A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis |
5 |
| Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs |
5 |
| Estimating parameters of nonlinear dynamic systems in pharmacology using chaos synchronization and grid search |
5 |
| Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale |
5 |
| A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans |
5 |
| Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
5 |
| Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens |
5 |
| Transit and lifespan in neutrophil production: implications for drug intervention |
5 |
| Boolean network modeling in systems pharmacology |
5 |
| The use of PBPK modeling across the pediatric age range using propofol as a case |
4 |
| Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis |
4 |
| Concentration-response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent |
4 |
| Challenge model of TNF alpha turnover at varying LPS and drug provocations |
4 |
| Operating characteristics of stepwise covariate selection in pharmacometric modeling |
4 |
| Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics |
4 |
| gPKPDSim: a SimBiology((R))-based GUI application for PKPD modeling in drug development |
4 |
| Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics |
3 |
| Monte Carlo simulations in drug release |
3 |
| Structural identifiability for mathematical pharmacology: models of myelosuppression |
3 |
| Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development |
3 |
| Leveraging model-informed approaches for drug discovery and development in the cardiovascular space |
3 |
| A translational platform PBPK model for antibody disposition in the brain |
3 |
| Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy |
3 |
| Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs |
3 |
| Orphan drug development: the increasing role of clinical pharmacology |
3 |
| Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts |
3 |
| Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab |
3 |
| Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex |
3 |
| Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma |
3 |
| An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients |
2 |
| Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals |
2 |
| Modeling the acute effects of exercise on insulin kinetics in type 1 diabetes |
2 |
| Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients |
2 |
| Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia |
2 |
| Model reduction in mathematical pharmacology |
2 |
| Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2% |
2 |
| Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim |
2 |
| Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma |
2 |
| Development of visual predictive checks accounting for multimodal parameter distributions in mixture models |
2 |
| Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis |
2 |
| Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems |
2 |
| A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies |
2 |
| Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach |
2 |
